Novo Nordisk Scales Oral GLP-1 Production with €432M ($506M) Investment in Ireland Facility

On March 2, 2026, Novo Nordisk announced a €432 million ($506 Million) investment to expand their tableting facility in Athlone, Ireland.¹ The expansion is designed to provide essential manufacturing capacity for current and future GLP-1 treatments. The project underscores the industrial scale and infrastructure required to produce oral GLP-1s effectively for a global market.

How Will the Facility Expansion Enhance Manufacturing Capabilities?

The project involves the extensive upgrade and retrofit of an existing 45-acre site to meet the rigorous standards of modern drug production.¹ This infrastructure investment is a key component of a broader CMC strategy to ensure a stable and scalable supply of oral medications. Construction activities have already commenced and are scheduled for a phased completion between late 2027 and 2028. The 260 employees currently stationed at the site will prioritize environmental sustainability and operational efficiency. As an EVP might oversee such large-scale capital projects, this expansion reflects a long-term commitment to Ireland, where the company continues to advance its heritage in chronic disease care.

What Is the Strategic Value of the Ireland Hub for International Markets?

The Athlone facility is positioned to serve as a critical manufacturing hub for markets outside the US.¹ By localizing production to meet international demand, the supply chain for metabolic treatments becomes more resilient against global distribution challenges. Kasper Bødker Mejlvang, EVP CMC & Product Supply, Novo Nordisk, highlighted the importance of this growth, in a press release,¹ “With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the US.”

This development is not merely about physical infrastructure but about the capability to deliver scientific breakthroughs to millions of patients worldwide.¹ As Mejlvang explains,¹ “This investment, a historic milestone for Novo Nordisk in Ireland, marks our continued commitment to Ireland and our highly skilled employees in Athlone while allowing us to make a difference for millions of people living with serious chronic diseases.” By integrating these expanded capabilities, the site will support the ongoing effort to expand access to medicines and drive change in the treatment of chronic conditions.

How Else Is Novo Nordisk Expanding Its GLP-1 Development?

Complementing the Athlone infrastructure investment, Novo Nordisk has entered a strategic partnership with Vivtex designed to establish the next generation of oral biologics.² This collaboration focuses on overcoming the limited gastrointestinal absorption that traditionally necessitates injectable administration for peptide and protein therapeutics. By utilizing a robotics-driven platform and a proprietary high-throughput screening system—described as a gastrointestinal tract on a chip—researchers can simulate human intestinal absorption with high correlation. Thomas von Erlach, CEO and co-founder, Vivtex, noted, in a press release,² “Making biologics oral has been one of the most difficult challenges in drug delivery.” This technology integrates computational modeling and artificial intelligence to screen thousands of formulations daily, facilitating the identification of candidates with consistent human performance.

How Does This Research Collaboration Impact the Long-Term Manufacturing Pipeline?

The partnership aims to expand the availability of oral therapies for obesity, diabetes, and associated comorbidities.² Following the initial research phase, the responsibility for global development, regulatory activities, and manufacturing will be assumed by internal teams. Brian Vandahl, SVP of Therapeutics Discovery, Novo Nordisk, stated in a press release,² “Novo Nordisk has been at the forefront of innovation in protein and peptide engineering for several decades, and not least within the oral formulation of peptides. We launched the first-ever oral biologic more than five years ago and have recently launched the world's first oral biologic for obesity.” Under the agreement, Vivtex is eligible for up to $2.1 billion in payments plus royalties, highlighting the significant capital being deployed to transition biologics from syringes to tablets. These investments in both screening technology and physical capacity represent a dual approach to securing the future of oral metabolic medicine. Utilizing AI and advanced screening ensures that the pipeline remains robust enough to fill the expanding production lines in Ireland and beyond.

References

1. Novo Nordisk. Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland. Published March 2, 2026. Accessed March 2, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916508
2. Novo Nordisk; Vivtex Corporation. Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes. Published February 25, 2026. Accessed March 2, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916506